Skip to content

BCBS North Carolina

Does BCBS North Carolina cover Wegovy?

It depends on your benefits. BCBS North Carolina covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • BCBS North Carolina Employer / Commercial Insurance prior authorization policy

    BCBS North Carolina · PA policy · Employer

    Effective July 1, 2026. Verified July 16, 2026.

    View PDF Download Original insurer source
  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review July 16, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

Qualification pathways

You can qualify through any one of these.

Adult weight loss — obesity (BMI ≥ 30)

All of:

  • Patient is 18 years of age or older
  • Diagnosis of obesity AND BMI ≥ 30 kg/m2
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Adult weight loss — Asian descent (BMI ≥ 25)

All of:

  • Patient is 18 years of age or older
  • Diagnosis of obesity AND BMI ≥ 25 kg/m2
  • Patient is of South Asian, Southeast Asian, or East Asian descent
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Adult weight loss — overweight with comorbidity (BMI ≥ 27)

All of:

  • Patient is 18 years of age or older
  • BMI ≥ 27 kg/m2
  • At least one weight-related comorbidity/risk factor (e.g., CVD, CAD, HTN, OSA, knee-osteoarthritis, T2DM, dyslipidemia, PCOS, NASH/NAFLD, asthma, COPD)
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Pediatric weight loss (ages 12-17)

All of:

  • Patient is 12-17 years of age
  • Wegovy (semaglutide) 0.25mg, 0.5mg, 1mg, 1.7mg, or 2.4mg injection
  • Diagnosis of obesity AND BMI > 95th percentile for age and sex
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Documentation to bring

  • Baseline BMI documentation
  • Documentation of obesity diagnosis or weight-related comorbidity
  • For Asian descent patients: documentation of ancestry (South Asian, Southeast Asian, or East Asian)
  • Documentation that provider addressed lifestyle modification requirement (calorie restriction and increased physical activity)
  • Documentation of 6-month lifestyle modification attempt with failure to achieve 1 lb/week weight loss, OR documentation of weight-related comorbidity warranting immediate medication intervention
  • Documentation that patient is not concurrently using another GLP-1 receptor agonist
  • Documentation that patient is not concurrently using another weight loss medication
  • Confirmation of anti-obesity medication coverage benefits
  • For pediatric patients (12-17): documentation of BMI > 95th percentile for age and sex

Quantity limits

  • 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL — 4 pens per 28 days
  • 1.5 mg tablet — 1 tablet per day
  • 4 mg tablet — 1 tablet per day
  • 9 mg tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: At least 5% reduction in BMI.
  • Renewal: Adults: weight loss ≥ 5% from baseline (prior to initiation). Ages 12-17: BMI reduction ≥ 5% from baseline. Patient must retain anti-obesity medication coverage benefits. Initial BMI, lifestyle, and comorbidity criteria are not re-verified at continuation.

Not covered when

  • Concurrent use of another GLP-1 receptor agonist
  • Concurrent use of another weight loss medication
  • Non-formulary products require Non-formulary Exception Criteria

Policy note: Policy covers Wegovy injection (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg), Wegovy HD injection (7.2mg), and Wegovy tablets under one policy. This entry covers injection (standard doses) and tablets for weight loss indication. Quantity limits listed only apply to doses with explicit QL; maintenance doses (1.7mg, 2.4mg) do not have a listed quantity limit per May 2024 update. Quantity limit exception criteria allows a 90-day titration period override. Policy name is 'Anti-Obesity Agents – NC Standard'. Reviewed by Blue Cross NC P&T Committee annually in Q1.

Policy effective July 1, 2026 · verified July 16, 2026 · source: BCBS North Carolina Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease with qualifying event

All of:

  • Patient is 18 years of age or older
  • Using medication to reduce risk of MACE (cardiovascular death, non-fatal MI, or non-fatal stroke)
  • Established cardiovascular disease (defined as: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm, all of atherosclerotic origin)
  • BMI ≥ 27 kg/m2
  • Patient will use optimized pharmacotherapy for established cardiovascular disease in combination with Wegovy
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • History of myocardial infarction
  • History of stroke
  • Peripheral artery disease defined by intermittent claudication with ankle-brachial index < 0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of established cardiovascular disease (CAD, ACS, MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid/arterial stenosis, or PAD of atherosclerotic origin)
  • Documentation of qualifying CV event history (MI, stroke, or PAD with ABI < 0.85, revascularization, or amputation)
  • Baseline BMI ≥ 27 kg/m2
  • Documentation of current use of optimized pharmacotherapy for established cardiovascular disease or clinical reason it is not appropriate
  • Documentation that patient is not concurrently using another GLP-1 receptor agonist
  • Documentation that patient is not concurrently using another weight loss medication
  • Confirmation of anti-obesity medication coverage benefits

Quantity limits

  • 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL — 4 pens per 28 days
  • 1.5 mg tablet — 1 tablet per day
  • 4 mg tablet — 1 tablet per day
  • 9 mg tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: Patient must continue optimized pharmacotherapy for established CVD in combination with Wegovy AND demonstrate a positive clinical response. Initial CVD, BMI, and GDMT requirements are re-verified at continuation for this indication.

Not covered when

  • Concurrent use of another GLP-1 receptor agonist
  • Concurrent use of another weight loss medication

Policy note: Applies to both Wegovy injection (0.25mg–2.4mg) and Wegovy tablets. CV risk reduction indication requires established CVD with at least one specific qualifying event (MI, stroke, or PAD) plus BMI ≥ 27. 'Optimized pharmacotherapy' is not further specified in the policy. Excludes diabetes is false — the policy does not exclude diabetic patients from this indication. Definition of established CVD was added June 2025.

Policy effective July 1, 2026 · verified July 16, 2026 · source: BCBS North Carolina Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

Qualification pathways

You can qualify through any one of these.

MASH with moderate-to-advanced fibrosis (F2-F3)

All of:

  • Patient is 18 years of age or older
  • Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Moderate to advanced liver fibrosis consistent with fibrosis stage F2 or F3 confirmed by one of: liver biopsy, VCTE, ELF score, or MRE
  • No significant alcohol consumption
  • No decompensated cirrhosis
  • No other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
  • Prescriber is a specialist (e.g., hepatologist, gastroenterologist) OR prescriber has consulted with a specialist
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Patient has anti-obesity medication coverage benefits

Documentation to bring

  • Documentation of MASH diagnosis
  • Fibrosis staging documentation confirming F2 or F3 via one of: liver biopsy, vibration-controlled transient elastography (VCTE), enhanced liver fibrosis (ELF) score, or magnetic resonance elastography (MRE)
  • Documentation confirming absence of significant alcohol consumption
  • Documentation confirming absence of decompensated cirrhosis
  • Documentation confirming absence of other liver disease (Wilson's disease, hepatocellular carcinoma, hepatitis, etc.)
  • Documentation that prescriber is a hepatologist/gastroenterologist specialist OR has consulted with such a specialist
  • Documentation that patient is not concurrently using another GLP-1 receptor agonist
  • Documentation that patient is not concurrently using another weight loss medication
  • Confirmation of anti-obesity medication coverage benefits

Quantity limits

  • 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL — 4 pens per 28 days
  • 1.5 mg tablet — 1 tablet per day
  • 4 mg tablet — 1 tablet per day
  • 9 mg tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: Patient must demonstrate a positive clinical response while using the medication. Patient must not have significant alcohol consumption, decompensated cirrhosis, or any other liver disease. Specialist involvement (or consultation) must continue.

Not covered when

  • Significant alcohol consumption
  • Decompensated cirrhosis
  • Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
  • Concurrent use of another GLP-1 receptor agonist
  • Concurrent use of another weight loss medication

Policy note: MASH indication added January 2026. Applies to Wegovy injection (0.25mg–2.4mg) only per the criteria section structure (section c.iii). No explicit lookback periods stated for fibrosis confirmation methods. No BMI threshold is specified for this indication. Noncirrhotic MASH with F2-F3 fibrosis is the target population (per FDA labeling mirrored in policy).

Policy effective July 1, 2026 · verified July 16, 2026 · source: BCBS North Carolina Employer / Commercial Insurance prior authorization policy · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

BCBS North Carolina has separate Wegovy policies that don't depend on that benefit:

Questions people ask
Does BCBS North Carolina cover Wegovy?
It depends on your benefits. BCBS North Carolina covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Wegovy approval last with BCBS North Carolina?
Weight Loss — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months. Liver Disease (MASH) — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months.
What does BCBS North Carolina require to renew Wegovy?
Weight Loss — Applies to Employer plans. At least 5% reduction in BMI. Adults: weight loss ≥ 5% from baseline (prior to initiation). Ages 12-17: BMI reduction ≥ 5% from baseline. Patient must retain anti-obesity medication coverage benefits. Initial BMI, lifestyle, and comorbidity criteria are not re-verified at continuation. Heart Disease Risk Reduction — Applies to Employer plans. Patient must continue optimized pharmacotherapy for established CVD in combination with Wegovy AND demonstrate a positive clinical response. Initial CVD, BMI, and GDMT requirements are re-verified at continuation for this indication. Liver Disease (MASH) — Applies to Employer plans. Patient must demonstrate a positive clinical response while using the medication. Patient must not have significant alcohol consumption, decompensated cirrhosis, or any other liver disease. Specialist involvement (or consultation) must continue.
How current is this information?
The oldest review date among the policies on this page is July 16, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS North Carolina: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: North Carolina Medicaid, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota

All insurance plans · All medications

Summary of BCBS North Carolina's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.